Use of mylk in preparation of prostate cancer prognosis evaluation kit

Abstract

The application relates to the technical field of diagnosis, in particular to application of MYLK as a biomarker in preparation of a prostate cancer prognosis evaluation kit, and a prostate cancer patient prognosis evaluation kit and evaluation system. The application provides an evaluation system and method for evaluating the prognosis and immune microenvironment state of a prostate cancer patient based on the expression level of MYLK, which has good stability, accuracy and operability, can realize stratified management and individualized treatment guidance of the patient risk, and has significant clinical and social values.

Description

Technical Field

[0001] This invention relates to the field of tumor molecular diagnostic technology, specifically the application of MYLK in the preparation of a prognostic assessment kit for prostate cancer. Background Technology

[0002] Prostate cancer, a malignant tumor originating in the prostate tissue, is one of the most serious diseases threatening the health of elderly men worldwide. In recent years, with the development of early diagnostic strategies such as prostate-specific antigen (PSA) screening, MRI, and prostate biopsy, as well as the development of targeted drugs for castration-resistant prostate cancer (CRPC) such as abiraterone and enzalutamide, the prognosis of PRAD patients has significantly improved. However, PRAD is a heterogeneous disease. Some PRAD subtypes exhibit a highly aggressive phenotype and are prone to early metastasis, especially bone metastasis, which is often a major cause of death in PRAD patients. This indicates that existing risk stratification methods are insufficient to reflect the biological differences among patient tumors.

[0003] Currently, clinical treatment plans largely rely on traditional pathological parameters and staging systems. While these pathological parameters have some value in guiding clinical decisions, they cannot effectively differentiate between patients with the same stage but vastly different prognoses, nor can they predict the response of individual patients to immunotherapy drugs (such as PD-1 or PD-L1 blockers). This limits the achievement of precision treatment strategies.

[0004] In recent years, with the deepening research on the tumor immune microenvironment (TIME), researchers are attempting to mine molecular features with predictive capabilities for immune responses or prognosis through transcriptome data. However, some potential molecular markers reported so far still suffer from problems such as unstable detection results, low specificity, and highly heterogeneous expression levels, making them difficult to apply independently for prognostic assessment.

[0005] In summary, existing technologies for prognostic assessment of prostate cancer generally have the following shortcomings: 1. Lack of independent molecular biomarkers that can be stably detected in clinical tissue samples; 2. No method to integrate tumor immune characteristics, patient survival information and biomarker expression systems to form an assessment method that is easy to promote.

[0006] The MYLK gene, located on chromosome 3qcen-q21 with a DNA span of approximately 270 kb, encodes myosin light chain kinase (MLCK). Three isoforms of the MYLK gene have been reported (MYLK 1, MYLK 2, and MYLK 3), with MYLK 1 exhibiting a more complex structure and wider tissue distribution. Under physiological conditions, MYLK activates myosin II, participating in various processes such as cell adhesion and migration, endocytosis and exocytosis, maintenance of epithelial and endothelial barriers, cell proliferation, and muscle contraction. Under pathological conditions, MYLK actively participates in the oncogenic transformation and malignant progression of various tumors, including leiomyosarcoma, colorectal cancer, hepatocellular carcinoma, breast cancer, and hypopharyngeal carcinoma. However, the specific expression characteristics of MYLK in prostate cancer, its pan-cancer impact on patient prognosis, tumor microenvironment (TME), and immunotherapy have not been systematically elucidated.

[0007] However, there are currently no reports on the use of MYLK in prognostic assessment of prostate cancer. Summary of the Invention

[0008] The purpose of this invention is to provide the application of MYLK in prognostic assessment and immune microenvironment evaluation of prostate cancer. The assessment system is stable, reproducible, has strong independent predictive power, and is easy to operate clinically, thus overcoming the accuracy deficiencies of existing assessment systems in the era of immunotherapy. By integrating tissue RNA sequencing data (The Cancer Genome Atlas, TCGA), immunohistochemical staining (IHC) results, and immune-related feature analysis, the molecular diagnostic value of MYLK as an independent poor prognostic indicator is clarified.

[0009] To achieve the above objectives, this invention employs the following technical solution to construct a risk assessment and immune prediction system for MYLK in prostate cancer:

[0010] 1. Molecular detection method: The expression level of MYLK protein in prostate cancer tissue samples was detected by IHC, and patients were divided into high- or low-MYLK expression groups based on the expression level. This grouping method can stably distinguish different prognostic populations. KM survival analysis verified the significant differences in overall survival (OS) and progression-free survival (PFS) between the high- and low-MYLK expression groups, with patients with high MYLK expression showing significantly reduced OS and PFS.

[0011] 2. Construction of an independent prognostic model: Multivariate Cox regression analysis of 96 prostate cancer patients showed that MYLK expression level maintained statistically significant predictive ability after controlling for variables such as age, Gleason score, T stage, and tPSA level. The low MYLK expression group had significantly longer overall survival (OS) and progression-free survival (PFS) compared to the high expression group (OS: HR = 7.4e-09, P < 0.001; PFS: HR = 4.6e-09, P < 0.001), further demonstrating its role as an independent poor prognostic factor for prostate cancer.

[0012] 3. Construction of Clinical Scoring System: This invention constructs a prognostic scoring system for prostate cancer patients based on clinical variables such as MYLK expression level and T stage, and establishes a visual nomogram using a multivariate Cox proportional hazards model. This nomogram can provide individual patients with predictions of overall survival (OS) probability at 2, 3, 4, and 5 years, helping clinicians achieve intuitive and quantitative risk assessment and personalized decision support. In the nomogram scoring system constructed in this invention, each variable is assigned a corresponding weight score according to its impact on patient prognosis, thereby achieving quantitative prediction of overall survival probability. Specifically, patients aged 46-80 years received 0 points, and those aged 81-86 years received 22 points; regarding the Gleason score, Grade 9 patients received 0 points, Grade 6 patients received 7.5 points, and Grade 7-8 patients received 95 points; in T stage, T1-3 patients received 0 points, and T4 patients received 22 points; regarding tPSA level, high tPSA (tPSA > 14 ng / ml) patients received 0 points, and low tPSA (tPSA ≤ 14 ng / ml) patients received 5 points; finally, regarding MYLK expression grouping, high expression received 100 points, and low expression received 0 points. After adding up the scores of the above items to obtain the total score, the overall survival (OS) probability of patients at 2, 3, 4, and 5 years can be estimated using a nomogram model, providing accurate individualized risk assessment basis for prostate cancer patients. To evaluate the predictive power of this joint model, this invention uses the Receiver Operating Characteristic curve (ROC) and the corresponding Area Under the Curve (AUC) for quantitative validation. The results show that the joint scoring system exhibits excellent predictive efficacy at multiple time points: the 3-year AUC is 0.689, the 4-year AUC is 0.691, and the 5-year AUC is 0.859, indicating that the model possesses extremely high sensitivity and specificity in medium- and long-term survival prediction.

[0013] 4. Immunological Characterization: Systematic correlation analysis of CIBERSORT immune infiltration data from multiple cancer types revealed that MYLK was significantly correlated with various immune cell components across different tumor types. In prostate cancer, MYLK was negatively correlated with macrophage M1 (R = -0.24). These results suggest that high MYLK expression may mark the activation of inflammatory responses in the tumor microenvironment, reflecting its role in regulating tumor immune status.

[0014] 5. Visualization Platform and Staining Standardization: This invention combines immunohistochemistry (IHC) staining technology to establish a standardized MYLK detection process based on tissue microarray (TMA), ensuring visualization, semi-quantification, and high reproducibility of the detection.

[0015] This invention fills the gap in the current lack of stable and independent prognostic factors by introducing the molecular marker MYLK into the diagnosis and assessment system for prostate cancer, providing a new tool for the individualized management of prostate cancer patients and showing good market application prospects.

[0016] Based on the above technical solution, the first aspect of the present invention provides the application of MYLK as a biomarker in the preparation of a prognostic assessment kit for prostate cancer.

[0017] In a second aspect, the invention provides the use of a reagent for detecting MYLK expression levels in the preparation of a prognostic assessment kit for prostate cancer.

[0018] Furthermore, the reagent used to detect MYLK expression levels is a reagent for detecting MYLK expression levels in prostate cancer tissue.

[0019] Furthermore, the prostate cancer tissue sample can be obtained from postoperative tumor tissue or puncture biopsy specimens.

[0020] Furthermore, the reagents used to detect MYLK expression levels in prostate cancer tissues are selected from those used for detection by immunohistochemical staining (IHC), qRT-PCR, RNA in situ hybridization (RNAscope), or digital PCR.

[0021] Furthermore, the reagents for detecting MYLK expression levels in biological samples include antibodies that specifically recognize human MYLK and immunohistochemical reagents.

[0022] This invention combines immunohistochemical staining (IHC) technology to establish a standardized MYLK detection workflow based on tissue microarrays (TMA), ensuring visualization, semi-quantification, and high reproducibility. The specific steps are as follows: Surgically removed tumor and normal tissue samples are sequentially fixed in formaldehyde, embedded in paraffin, and serially sectioned, followed by the construction of a tissue microarray (TMA). After dewaxing and hydration, the microarray is subjected to antigen retrieval using a citrate antigen retrieval solution at pH 6.0, exposing the target antigen MYLK (primary antibody: Proteintech, 21642-1-AP, dilution 1:200), followed by staining and development. The IHC expression scoring system combines two dimensions: staining intensity and staining area. The IHC expression scoring system uses the H-score standard. This scoring method is based on the H-score system: H-score = ∑(pi × i). The specific calculation method is: (percentage of weakly positive cells × 1) + (percentage of moderately positive cells × 2) + (percentage of strongly positive cells × 3). The final IHC score ranges from 0 to 300. An IHC score of 0-125 indicates low MYLK expression, while an IHC score of 126-300 indicates high MYLK expression.

[0023] Furthermore, high MYLK expression resulted in significantly shorter overall survival (OS) and progression-free survival (PFS) compared to low expression.

[0024] A third aspect of the invention provides the application of a reagent for detecting MYLK expression levels in combination with other clinical variables in the preparation of a prognostic assessment kit for prostate cancer; the other clinical variables include age, Gleason score, T stage, and tPSA level.

[0025] In a fourth aspect, the present invention provides a prognostic assessment kit for prostate cancer, the kit comprising reagents for detecting MYLK expression levels.

[0026] In a fifth aspect, the present invention provides a prognostic prediction model for prostate cancer, wherein the prediction model uses MYLK expression level in prostate cancer tissue, age, Gleason score, T stage, and tPSA level as input variables, and predicts the prognosis of prostate cancer patients by calculating a risk score.

[0027] Furthermore, the present invention, through, as Figure 5 The nomogram scoring system shown predicts the overall survival (OS) probability of prostate cancer patients at 2, 3, 4, and 5 years.

[0028] This invention constructs a prognostic scoring system for prostate cancer patients based on clinical variables such as MYLK expression level and T stage, and establishes a visual nomogram using a multivariate Cox proportional hazards model. Figure 3 As shown, this nomogram can provide individual patients with predictions of overall survival (OS) probabilities over 2, 3, 4, and 5 years, helping clinicians achieve intuitive and quantitative risk assessment and personalized decision support. In the nomogram scoring system constructed in this invention, each variable is assigned a corresponding weight score based on its impact on patient prognosis, thereby achieving quantitative prediction of overall survival probability.

[0029] Specifically, patients aged 46-80 years received 0 points, and those aged 81-86 years received 22 points; regarding the Gleason score, Grade 9 patients received 0 points, Grade 6 patients received 7.5 points, and Grade 7-8 patients received 95 points; in T stage, T1-3 patients received 0 points, and T4 patients received 22 points; regarding tPSA level, high tPSA (tPSA > 14 ng / ml) patients received 0 points, and low tPSA (tPSA ≤ 14 ng / ml) patients received 5 points; finally, regarding MYLK expression grouping, high expression received 100 points, and low expression received 0 points. After adding up the scores of the above items to obtain the total score, the overall survival (OS) probability of patients at 2, 3, 4, and 5 years can be estimated using a nomogram model, providing accurate individualized risk assessment basis for prostate cancer patients.

[0030] In the nomogram scoring system based on MYLK expression and other clinical variables constructed in this invention, the patient's total score can be used to intuitively predict the overall survival (OS) probability at different time points. Specifically: for two-year survival prediction, a score of 117 corresponds to a survival probability of approximately 0.95, 125 to 0.90, 134 to 0.80, and 143 to 0.60; for three- and four-year survival prediction, a score of 109 corresponds to a survival probability of approximately 0.95, 144 to 0.90, 118 to 0.80, 126 to 0.90, 135 to 0.60, and 142 to 0.40; for five-year survival prediction, a score of 88 corresponds to a survival probability of approximately 0.95, 96 to 0.90, 105 to 0.80, 114 to 0.60, 121 to 0.40, and 132 to 0.10.

[0031] A fifth aspect of the present invention provides a system for predicting the prognosis of prostate cancer, comprising:

[0032] The data acquisition module is used to acquire MYLK expression levels, age, Gleason score, T stage, and tPSA levels in prostate cancer tissue.

[0033] The prognostic assessment module predicts the risk score of prostate cancer patients based on the data obtained by the data acquisition module and outputs the risk score; the prognostic assessment module includes the prostate cancer prognostic prediction model as described above;

[0034] The output module outputs the prediction result based on the risk score.

[0035] Furthermore, the prediction results are as follows: Based on the risk score, the overall survival (OS) probability for prostate cancer patients at 2, 3, 4, and 5 years is predicted. For 2-year survival prediction, a score of 117 corresponds to a survival probability of approximately 0.95, 125 to 0.90, 134 to 0.80, and 143 to 0.60. For 3- and 4-year survival prediction, a score of 109 corresponds to a survival probability of approximately 0.95, 144 to 0.90, 118 to 0.80, 126 to 0.90, 135 to 0.60, and 142 to 0.40. For 5-year survival prediction, a score of 88 corresponds to a survival probability of approximately 0.95, 96 to 0.90, 105 to 0.80, 114 to 0.60, 121 to 0.40, and 132 to 0.10.

[0036] In a sixth aspect, the present invention provides a computer-readable storage medium storing a computer program that, when executed by a processor, performs the functions of the system described above.

[0037] The advantages of this invention are:

[0038] 1. This invention provides a method for assessing the prognosis and immune microenvironment status of prostate cancer patients based on MYLK expression levels. This method exhibits good stability, accuracy, and operability, enabling stratified risk management and individualized treatment guidance for patients, demonstrating significant clinical and social value. In a retrospective clinical cohort constructed in this invention, immunohistochemical staining and digital scoring analysis of MYLK protein in tumor tissue samples from prostate cancer patients, combined with RNA expression data and survival information from the TCGA database, systematically validated the molecular diagnostic value of MYLK as an independent adverse prognostic factor. KM survival analysis showed that high MYLK expression was significantly associated with shortened overall survival (OS) and progression-free survival (PFS) in prostate cancer patients. Multivariate Cox regression model further confirmed that after controlling for other clinical factors (such as age, Gleason score, T stage, and tPSA level), the high MYLK expression group was still a statistically significant independent poor prognostic indicator compared with the low expression group (OS: HR = 7.4e-09, P < 0.001; PFS: HR = 4.6e-09, P < 0.001).

[0039] 2. Furthermore, the combined scoring system (MYLK + other clinical variables) proposed in this invention exhibits excellent predictive performance. The AUC value under the ROC curve shows that it has extremely high sensitivity and specificity in predicting 3- to 5-year survival, significantly superior to single clinical indicators. Regarding tumor immune characteristics, high MYLK expression in prostate cancer is negatively correlated with anti-inflammatory immune cells (such as macrophage M1), suggesting that it may reflect the state of tumor immune activation.

[0040] In summary, this invention establishes a stable, reproducible, and clinically applicable MYLK prostate cancer prognostic assessment and immunophenotyping system through an integrated strategy of IHC detection, prognostic modeling, and immunophenotyping. This system not only enables early identification and precise treatment guidance for high-risk patients but also has potential broad-spectrum tumor immunophenotyping applications. Its promotion will help optimize prognostic management for prostate cancer patients, reduce the burden of overtreatment, and improve the level of personalized medicine, demonstrating significant social benefits and economic potential. Attached Figure Description

[0041] Figure 1 Immunohistochemical staining results of MYLK in prostate cancer tissue reveal the differences in its expression in tumor tissues of different patients, and intuitively reflect the localization and expression intensity of this protein in tumor tissues.

[0042] Figure 2 This image shows a comparison of immunohistochemical staining results between normal prostate tissue and prostate cancer tissue. Combined with samples from a clinical cohort of prostate cancer, it illustrates the distribution trend and statistical significance of MYLK in tumor and non-tumor tissues.

[0043] Figure 3 The Kaplan-Meier (KM) survival analysis plot, grouped according to MYLK expression levels, includes overall survival (OS) and progression-free survival (PFS), indicating that high MYLK expression is significantly associated with poor prognosis.

[0044] Figure 4 The results of MYLK in multivariate Cox regression analysis are shown, including a forest plot, which demonstrates the role of MYLK as an independent prognostic factor after controlling for clinical factors. Meanwhile, the predictive efficacy of the ROC curve analysis combined with the scoring system is demonstrated, reflecting its application value in clinical risk prediction.

[0045] Figure 5 This is a nomogram constructed based on a multivariate Cox model, which combines clinical parameters such as MYLK expression level, age, Gleason score, T stage, and tPSA level to predict the survival probability of patients within 3 to 5 years, thus assisting in individualized clinical decision-making.

[0046] Figure 6 This is a heatmap showing the correlation between the major immune cell components and MYLK expression levels in the prostate cancer immune microenvironment. Based on the analysis results using the CIBERSORT algorithm, the potential role of MYLK in tumor immune regulation and its application value in immune assessment are revealed. Detailed Implementation

[0047] The specific implementation methods provided by the present invention will be described in detail below with reference to the embodiments.

[0048] Example 1: Identifying the Expression Characteristics and Prognostic Value of MYLK in Prostate Cancer by Integrating Multi-omics Data

[0049] Based on tissue RNA sequencing data of prostate cancer samples from the TCGA database, combined with clinical survival information, the relationship between MYLK expression levels and patient survival outcomes was assessed. Survival analysis showed that patients with high MYLK expression had significantly shorter overall survival (OS) and progression-free survival (PFS), suggesting it may be a poor prognostic factor. Multivariate Cox regression analysis further validated its independence; after controlling for variables such as age, sex, T stage, and Fuhrman classification, high MYLK expression remained significantly associated with an increased risk of death (OS: HR = 7.4e-09, P < 0.001; PFS: HR = 4.6e-09, P < 0.001). Figure 4 ).

[0050] Example 2: Detection of MYLK protein expression level and establishment of immunohistochemical scoring criteria

[0051] To verify the consistency of protein expression at the RNA level and establish a standardized detection procedure, immunohistochemical (IHC) staining was performed on 96 paraffin-embedded prostate cancer tissue specimens. All samples were dewaxed and antigen-retrieval processed before staining with MYLK antibody (Proteintech, 21642-1-AP, 1:200 dilution), and each specimen was independently scored by two pathologists. The scoring criteria combined staining intensity and staining area, with the final product used as the total score.

[0052] The IHC expression scoring system uses the H-score standard. This scoring method is based on the H-score system: H-score = ∑(pi × i). Specifically, it is calculated as: (percentage of weakly positive cells × 1) + (percentage of moderately positive cells × 2) + (percentage of strongly positive cells × 3). The final IHC score ranges from 0 to 300.

[0053] Based on the final score, tumor tissue samples were graded according to their MYLK expression levels, classifying prostate cancer patients into those with low MYLK expression (0-125 points) and those with high MYLK expression (126-300 points). Figure 1 ).

[0054] Example 3: Constructing a nomogram model and prognostic scoring system based on MYLK and clinical staging

[0055] A multivariate Cox regression model was constructed by combining MYLK expression levels with patient clinical staging information, and a nomogram was plotted to predict the overall survival (OS) probability at 2, 3, 4, and 5 years. In the nomogram scoring system, each variable was assigned a weighted score based on its impact on patient prognosis, thus achieving a quantitative prediction of overall survival probability. Specifically, patients aged 46-80 years received 0 points, and those aged 81-86 years received 22 points; regarding Gleason scores, Grade 9 patients received 0 points, Grade 6 patients received 7.5 points, and Grade 7-8 patients received 95 points; in T staging, T1-3 patients received 0 points, and T4 patients received 22 points; regarding tPSA levels, high tPSA (tPSA > 14 ng / ml) patients received 0 points, and low tPSA (tPSA ≤ 14 ng / ml) patients received 5 points; finally, in MYLK expression grouping, high expression received 100 points, and low expression received 0 points. After adding up the scores of the above items to obtain the total score, the overall survival (OS) probability of patients at 2, 3, 4 and 5 years can be estimated by using the nomogram model, providing accurate individualized risk assessment basis for prostate cancer patients.

[0056] In the nomogram scoring system based on MYLK expression and other clinical variables constructed in this invention, the patient's total score can be used to intuitively predict the overall survival (OS) probability at different time points. Figure 5Specifically: for two-year survival prediction, a score of 117 corresponds to a survival probability of approximately 0.95, 125 to 0.90, 134 to 0.80, and 143 to 0.60; for three- and four-year survival prediction, a score of 109 corresponds to a survival probability of approximately 0.95, 144 to 0.90, 118 to 0.80, 126 to 0.90, 135 to 0.60, and 142 to 0.40; for five-year survival prediction, a score of 88 corresponds to a survival probability of approximately 0.95, 96 to 0.90, 105 to 0.80, 114 to 0.60, 121 to 0.40, and 132 to 0.10. This nomogram demonstrated excellent performance in independent clinical cohorts. ROC curve analysis showed that the combined scoring system achieved AUC values ​​at multiple time points: 0.689 at 3 years, 0.691 at 4 years, and 0.859 at 5 years, demonstrating extremely high sensitivity and specificity. This model can provide an intuitive basis for individualized prognostic assessment and treatment decisions for prostate cancer patients.

[0057] Example 4: Immunological correlation analysis of MYLK in the immune microenvironment of prostate cancer

[0058] In this embodiment, the correlation between MYLK expression levels and different immune cell subsets in the tumor immune microenvironment was assessed using the CIBERSORT algorithm. In prostate cancer, MYLK was positively correlated with pro-inflammatory cells (such as resting CD4 memory T cells, R = 0.33) and negatively correlated with anti-inflammatory cells (such as macrophages, M1, R = -0.24). Figure 6 This suggests that high MYLK expression may reflect the state of immune activation in the tumor microenvironment and can be used to assess the propensity to respond to immunotherapy.

[0059] The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the embodiments described. Those skilled in the art can make various equivalent modifications or substitutions without departing from the spirit of the present invention, and these equivalent modifications or substitutions are all included within the scope defined by the claims of this application.

Claims

1. Application of reagents for detecting MYLK expression levels in the preparation of prostate cancer prognostic assessment kits.

2. The application according to claim 1, characterized in that, The reagent used to detect MYLK expression levels is specifically designed for detecting MYLK expression levels in prostate cancer tissues. This reagent is selected from those used for detection via immunohistochemical staining, qRT-PCR, RNA in situ hybridization, or digital PCR.

3. The application according to claim 2, characterized in that, Immunohistochemical staining IHC scores of 0-125 indicate low MYLK expression, while scores of 126-300 indicate high MYLK expression. High MYLK expression is associated with significantly shorter overall survival and progression-free survival compared to low MYLK expression.

4. A prostate cancer prognostic assessment kit, characterized in that, The kit contains reagents for detecting MYLK expression levels.

5. The application of reagents for detecting MYLK expression levels in combination with other clinical variables in the preparation of prostate cancer prognostic assessment kits, characterized in that... Other clinical variables mentioned include age, Gleason score, T stage, and tPSA level.

6. A prognostic prediction model for prostate cancer, characterized in that, The prediction model uses MYLK expression level in prostate cancer tissue, age, Gleason score, T stage, and tPSA level as input variables, and calculates a risk score to predict the prognosis of prostate cancer patients.

7. The prediction model according to claim 6, characterized in that, The overall survival probability of prostate cancer patients at 1, 2, 3, 4 and 5 years was predicted using the nomogram scoring system shown in Figure 5.

8. A system for predicting the prognosis of prostate cancer, characterized in that, include: The data acquisition module is used to acquire MYLK expression levels, age, Gleason score, T stage, and tPSA levels in prostate cancer tissue. The prognostic assessment module predicts the risk score of prostate cancer patients based on the data obtained by the data acquisition module and outputs the risk score; the prognostic assessment module includes the prostate cancer prognostic prediction model as described in claim 6. The output module outputs the prediction result based on the risk score.

9. The system according to claim 8, characterized in that, Patients aged 46-80 years received 0 points, and those aged 81-86 years received 22 points. Regarding the Gleason score, Grade 9 patients received 0 points, Grade 6 patients received 7.5 points, and Grade 7-8 patients received 95 points. In the T stage, T1-3 patients received 0 points, and T4 patients received 22 points. Regarding tPSA levels, patients with high tPSA (>14 ng / ml) received 0 points, and patients with low tPSA (≤14 ng / ml) received 5 points. Finally, in terms of MYLK expression, high expression received 100 points, and low expression received 0 points. The total score was obtained by adding all the scores together. For two-year survival predictions, a score of 117 corresponds to a survival probability of approximately 0.95, 125 to 0.90, 134 to 0.80, and 143 to 0.

60. For three- and four-year survival predictions, a score of 109 corresponds to a survival probability of approximately 0.95, 144 to 0.90, 118 to 0.80, 126 to 0.90, 135 to 0.60, and 142 to 0.

40. For five-year survival predictions, a score of 88 corresponds to a survival probability of approximately 0.95, 96 to 0.90, 105 to 0.80, 114 to 0.60, 121 to 0.40, and 132 to 0.

10.

10. A computer-readable storage medium, characterized in that, It stores a computer program, which, when executed by a processor, implements the functions of the system as described in claim 8.

Images